{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:04:19Z","timestamp":1780668259024,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Coordination of Scientific Research Projects at \u0130zmir Bakircay University","award":["BBAP.2023.004"],"award-info":[{"award-number":["BBAP.2023.004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Brain Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00221-026-07294-x","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:03:51Z","timestamp":1778666631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unveiling the neuroprotective potential of vortioxetine on inflammation in the cuprizone-induced demyelination model"],"prefix":"10.1007","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8186-4852","authenticated-orcid":false,"given":"Ay\u015fe","family":"\u00d6zkan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5064-2798","authenticated-orcid":false,"given":"Pelin","family":"Koca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"7294_CR1","doi-asserted-by":"crossref","first-page":"603979","DOI":"10.3389\/fphar.2020.603979","volume":"11","author":"S Alboni","year":"2020","unstructured":"Alboni S, Benatti C, Colliva C, Radighieri G, Blom JMC, Brunello N, Tascedda F (2020) Vortioxetine prevents lipopolysaccharide-induced memory impairment without inhibiting the initial inflammatory cascade. Front Pharmacol 11:603979","journal-title":"Front Pharmacol"},{"key":"7294_CR2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1515\/intox-2017-0006","volume":"10","author":"K Belovicova","year":"2017","unstructured":"Belovicova K, Bogi E, Csatlosova K, Dubovicky M (2017) Animal tests for anxiety-like and depression-like behavior in rats. Interdiscip Toxicol 10:40\u201343","journal-title":"Interdiscip Toxicol"},{"key":"7294_CR3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbr.2010.03.033","volume":"212","author":"Y Chen","year":"2010","unstructured":"Chen Y, Mao Y, Zhou D, Hu X, Wang J, Ma Y (2010) Environmental enrichment and chronic restraint stress in ICR mice: effects on prepulse inhibition of startle and Y-maze spatial recognition memory. Behav Brain Res 212:49\u201355","journal-title":"Behav Brain Res"},{"key":"7294_CR4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/02698811221090627","volume":"36","author":"MC Christensen","year":"2022","unstructured":"Christensen MC, Schmidt S, Grande I (2022) Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study. J Psychopharmacol 36:566\u2013577","journal-title":"J Psychopharmacol"},{"key":"7294_CR5","first-page":"36","volume":"40","author":"A D\u2019Agostino","year":"2015","unstructured":"D\u2019Agostino A, English CD, Rey JA (2015) Vortioxetine (brintellix): a new serotonergic antidepressant. P T 40:36\u201340","journal-title":"P T"},{"key":"7294_CR6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson R, Giovannoni G (2019) Multiple sclerosis: a review. Eur J Neurol 26:27\u201340","journal-title":"Eur J Neurol"},{"key":"7294_CR7","doi-asserted-by":"crossref","first-page":"14761","DOI":"10.1038\/s41598-017-15348-y","volume":"7","author":"A Dominguez-Soto","year":"2017","unstructured":"Dominguez-Soto A, Usategui A, Casas-Engel ML, Simon-Fuentes M, Nieto C, Cuevas VD, Vega MA, Pablos L, Corbi J, A.L (2017) Serotonin drives the acquisition of a profibrotic and anti-inflammatory gene profile through the 5-HT7R-PKA signaling axis. Sci Rep 7:14761","journal-title":"Sci Rep"},{"key":"7294_CR8","doi-asserted-by":"crossref","first-page":"119865","DOI":"10.1016\/j.lfs.2021.119865","volume":"283","author":"AM Emam","year":"2021","unstructured":"Emam AM, Saad MA, Ahmed NA, Zaki HF (2021) Vortioxetine mitigates neuronal damage by restricting PERK\/eIF2alpha\/ATF4\/CHOP signaling pathway in rats subjected to focal cerebral ischemia-reperfusion. Life Sci 283:119865","journal-title":"Life Sci"},{"key":"7294_CR9","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1084\/jem.20150237","volume":"214","author":"L Freeman","year":"2017","unstructured":"Freeman L, Guo H, David CN, Brickey WJ, Jha S, Ting JP (2017) NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes. J Exp Med 214:1351\u20131370","journal-title":"J Exp Med"},{"key":"7294_CR10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/1871527322666230321093133","volume":"23","author":"A Gil-Sanchez","year":"2024","unstructured":"Gil-Sanchez A, Canudes M, Valcheva P, Nogueras L, Gonzalez-Mingot C, Hervas JV, Peralta S, Solana M, Brieva L (2024) Effects of vortioxetine on cognition and fatigue in patients with multiple sclerosis and depression: a case series study. CNS Neurol Disord Drug Targets 23:395\u2013401","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"7294_CR11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fcvm.2017.00048","volume":"4","author":"N Herr","year":"2017","unstructured":"Herr N, Bode C, Duerschmied D (2017) The effects of serotonin in immune cells. Front Cardiovasc Med 4:48","journal-title":"Front Cardiovasc Med"},{"key":"7294_CR12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5493\/wjem.v4.i3.27","volume":"4","author":"RA Hoglund","year":"2014","unstructured":"Hoglund RA, Maghazachi AA (2014) Multiple sclerosis and the role of immune cells. World J Exp Med 4:27\u201337","journal-title":"World J Exp Med"},{"key":"7294_CR13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4088\/JCP.20r13682","volume":"82","author":"N Iovieno","year":"2021","unstructured":"Iovieno N, Papakostas GI, Feeney A, Fava M, Mathew SJ, Iosifescu DI, Murrough JW, Macaluso M, Hock RS, Jha MK (2021) Vortioxetine versus placebo for major depressive disorder: a comprehensive analysis of the clinical trial dataset. J Clin Psychiatry 82:10\u20134088","journal-title":"J Clin Psychiatry"},{"key":"7294_CR14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pharmthera.2016.04.001","volume":"163","author":"HO Kalkman","year":"2016","unstructured":"Kalkman HO, Feuerbach D (2016) Antidepressant therapies inhibit inflammation and microglial M1-polarization. Pharmacol Ther 163:82\u201393","journal-title":"Pharmacol Ther"},{"key":"7294_CR15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/mp.2016.167","volume":"23","author":"N Kappelmann","year":"2018","unstructured":"Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM (2018) Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry 23:335\u2013343","journal-title":"Mol Psychiatry"},{"key":"7294_CR16","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1038\/s41380-020-00994-y","volume":"26","author":"R Karayol","year":"2021","unstructured":"Karayol R, Medrihan L, Warner-Schmidt JL, Fait BW, Rao MN, Holzner EB, Greengard P, Heintz N, Schmidt EF (2021) Serotonin receptor 4 in the hippocampus modulates mood and anxiety. Mol Psychiatry 26:2334\u20132349","journal-title":"Mol Psychiatry"},{"key":"7294_CR17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","volume":"27","author":"C Katona","year":"2012","unstructured":"Katona C, Hansen T, Olsen CK (2012) A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 27:215\u2013223","journal-title":"Int Clin Psychopharmacol"},{"key":"7294_CR18","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.12740\/PP\/OnlineFirst\/151570","volume":"57","author":"AJ Krupa","year":"2023","unstructured":"Krupa AJ, Wojtasik-Bakalarz K, Siwek M (2023) Vortioxetine-pharmacological properties and use in mood disorders: the current state of knowledge. Psychiatr Pol 57:1109\u20131126","journal-title":"Psychiatr Pol"},{"key":"7294_CR19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nri.2015.10","volume":"16","author":"BJ Laidlaw","year":"2016","unstructured":"Laidlaw BJ, Craft JE, Kaech SM (2016) The multifaceted role of CD4(+) T cells in CD8(+) T cell memory. Nat Rev Immunol 16:102\u2013111","journal-title":"Nat Rev Immunol"},{"key":"7294_CR20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","volume":"47","author":"C Lucchinetti","year":"2000","unstructured":"Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707\u2013717","journal-title":"Ann Neurol"},{"key":"7294_CR21","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1089\/bfm.2021.0074","volume":"16","author":"K Marshall","year":"2021","unstructured":"Marshall K, Datta P, Rewers-Felkins K, Krutsch K, Baker T, Hale TW (2021) Transfer of the Serotonin Modulator Vortioxetine into Human Milk: A Case Series. Breastfeed Med 16:843\u2013845","journal-title":"Breastfeed Med"},{"key":"7294_CR22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1750-3639.2001.tb00385.x","volume":"11","author":"GK Matsushima","year":"2001","unstructured":"Matsushima GK, Morell P (2001) The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11:107\u2013116","journal-title":"Brain Pathol"},{"key":"7294_CR23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaut.2018.01.001","volume":"87","author":"AM McGinley","year":"2018","unstructured":"McGinley AM, Edwards SC, Raverdeau M, Mills KHG (2018) Th17 cells, gammadelta T cells and their interplay in EAE and multiple sclerosis. J Autoimmun 87:97\u2013108","journal-title":"J Autoimmun"},{"key":"7294_CR24","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1017\/S1461145714000546","volume":"17","author":"RS McIntyre","year":"2014","unstructured":"McIntyre RS, Lophaven S, Olsen CK (2014) A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 17:1557\u20131567","journal-title":"Int J Neuropsychopharmacol"},{"key":"7294_CR25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/mcne.1998.0715","volume":"12","author":"P Morell","year":"1998","unstructured":"Morell P, Barrett CV, Mason JL, Toews AD, Hostettler JD, Knapp GW, Matsushima GK (1998) Gene expression in brain during cuprizone-induced demyelination and remyelination. Mol Cell Neurosci 12:220\u2013227","journal-title":"Mol Cell Neurosci"},{"key":"7294_CR26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neulet.2006.03.042","volume":"402","author":"JP Mostert","year":"2006","unstructured":"Mostert JP, Sijens PE, Oudkerk M, De Keyser J (2006) Fluoxetine increases cerebral white matter NAA\/Cr ratio in patients with multiple sclerosis. Neurosci Lett 402:22\u201324","journal-title":"Neurosci Lett"},{"key":"7294_CR27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.imbio.2016.07.001","volume":"222","author":"K Nazimek","year":"2017","unstructured":"Nazimek K, Strobel S, Bryniarski P, Kozlowski M, Filipczak-Bryniarska I, Bryniarski K (2017) The role of macrophages in anti-inflammatory activity of antidepressant drugs. Immunobiology 222:823\u2013830","journal-title":"Immunobiology"},{"key":"7294_CR28","doi-asserted-by":"crossref","first-page":"108977","DOI":"10.1016\/j.neuropharm.2022.108977","volume":"208","author":"D Nemutlu Samur","year":"2022","unstructured":"Nemutlu Samur D, Akcay G, Yildirim S, Ozkan A, Ceker T, Derin N, Tanriover G, Aslan M, Agar A, Ozbey G (2022) Vortioxetine ameliorates motor and cognitive impairments in the rotenone-induced Parkinson\u2019s disease via targeting TLR-2 mediated neuroinflammation. Neuropharmacology 208:108977","journal-title":"Neuropharmacology"},{"key":"7294_CR29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1017\/S1092852913000540","volume":"19","author":"AL Pehrson","year":"2014","unstructured":"Pehrson AL, Sanchez C (2014) Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 19:121\u2013133","journal-title":"CNS Spectr"},{"key":"7294_CR30","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1523\/JNEUROSCI.5035-10.2011","volume":"31","author":"HB Pohl","year":"2011","unstructured":"Pohl HB, Porcheri C, Mueggler T, Bachmann LC, Martino G, Riethmacher D, Franklin RJ, Rudin M, Suter U (2011) Genetically induced adult oligodendrocyte cell death is associated with poor myelin clearance, reduced remyelination, and axonal damage. J Neurosci 31:1069\u20131080","journal-title":"J Neurosci"},{"key":"7294_CR31","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/brain\/awq359","volume":"134","author":"J Raasch","year":"2011","unstructured":"Raasch J, Zeller N, van Loo G, Merkler D, Mildner A, Erny D, Knobeloch KP, Bethea JR, Waisman A, Knust M, Del Turco D, Deller T, Blank T, Priller J, Bruck W, Pasparakis M, Prinz M (2011) IkappaB kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-kappaB in the central nervous system. Brain 134:1184\u20131198","journal-title":"Brain"},{"key":"7294_CR32","doi-asserted-by":"crossref","first-page":"14774","DOI":"10.1038\/s41598-017-15104-2","volume":"7","author":"A Rodriguez","year":"2017","unstructured":"Rodriguez A, Zhang H, Klaminder J, Brodin T, Andersson M (2017) ToxId: an efficient algorithm to solve occlusions when tracking multiple animals. Sci Rep 7:14774","journal-title":"Sci Rep"},{"key":"7294_CR33","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1523\/JNEUROSCI.5717-09.2010","volume":"30","author":"B Roozendaal","year":"2010","unstructured":"Roozendaal B, Hernandez A, Cabrera SM, Hagewoud R, Malvaez M, Stefanko DP, Haettig J, Wood MA (2010) Membrane-associated glucocorticoid activity is necessary for modulation of long-term memory via chromatin modification. J Neurosci 30:5037\u20135046","journal-title":"J Neurosci"},{"key":"7294_CR34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bdi.12373","volume":"18","author":"JD Rosenblat","year":"2016","unstructured":"Rosenblat JD, Kakar R, Berk M, Kessing LV, Vinberg M, Baune BT, Mansur RB, Brietzke E, Goldstein BI, McIntyre RS (2016) Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord 18:89\u2013101","journal-title":"Bipolar Disord"},{"key":"7294_CR35","doi-asserted-by":"crossref","first-page":"176929","DOI":"10.1016\/j.ejphar.2024.176929","volume":"982","author":"MS Shafiek","year":"2024","unstructured":"Shafiek MS, Mekky RY, Nassar NN, El-Yamany MF, Rabie MA (2024) Vortioxetine ameliorates experimental autoimmune encephalomyelitis model of multiple sclerosis in mice via activation of PI3K\/Akt\/CREB\/BDNF cascade and modulation of serotonergic pathway signaling. Eur J Pharmacol 982:176929","journal-title":"Eur J Pharmacol"},{"key":"7294_CR36","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/10253890.2018.1438405","volume":"21","author":"O Sturman","year":"2018","unstructured":"Sturman O, Germain PL, Bohacek J (2018) Exploratory rearing: a context- and stress-sensitive behavior recorded in the open-field test. Stress 21:443\u2013452","journal-title":"Stress"},{"key":"7294_CR37","first-page":"307","volume":"54","author":"K Suzuki","year":"1969","unstructured":"Suzuki K, Kikkawa Y (1969) Status spongiosus of CNS and hepatic changes induced by cuprizone (biscyclohexanone oxalyldihydrazone). Am J Pathol 54:307\u2013325","journal-title":"Am J Pathol"},{"key":"7294_CR38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/bph.14074","volume":"175","author":"M Talmon","year":"2018","unstructured":"Talmon M, Rossi S, Pastore A, Cattaneo CI, Brunelleschi S, Fresu LG (2018) Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes\/macrophages. Br J Pharmacol 175:113\u2013124","journal-title":"Br J Pharmacol"},{"key":"7294_CR39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/1570159X15666170717120343","volume":"17","author":"JM Vega-Riquer","year":"2019","unstructured":"Vega-Riquer JM, Mendez-Victoriano G, Morales-Luckie RA, Gonzalez-Perez O (2019) Five decades of cuprizone, an updated model to replicate demyelinating diseases. Curr Neuropharmacol 17:129\u2013141","journal-title":"Curr Neuropharmacol"},{"key":"7294_CR40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000334095","volume":"19","author":"XQ Yuan","year":"2012","unstructured":"Yuan XQ, Qiu G, Liu XJ, Liu S, Wu Y, Wang X, Lu T (2012) Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats. Neuroimmunomodulation 19:201\u2013208","journal-title":"Neuroimmunomodulation"},{"key":"7294_CR41","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s12031-013-0026-4","volume":"51","author":"A Zendedel","year":"2013","unstructured":"Zendedel A, Beyer C, Kipp M (2013) Cuprizone-induced demyelination as a tool to study remyelination and axonal protection. J Mol Neurosci 51:567\u2013572","journal-title":"J Mol Neurosci"},{"key":"7294_CR42","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3390\/cells9040843","volume":"9","author":"J Zhan","year":"2020","unstructured":"Zhan J, Mann T, Joost S, Behrangi N, Frank M, Kipp M (2020) The cuprizone model: dos and do nots. Cells 9:843","journal-title":"Cells"},{"key":"7294_CR43","doi-asserted-by":"crossref","first-page":"175909141772517","DOI":"10.1177\/1759091417725174","volume":"9","author":"W Zhen","year":"2017","unstructured":"Zhen W, Liu A, Lu J, Zhang W, Tattersall D, Wang J (2017) An alternative cuprizone-induced demyelination and remyelination mouse model. ASN Neuro 9:1759091417725174","journal-title":"ASN Neuro"},{"key":"7294_CR44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13024-022-00538-8","volume":"17","author":"M Zirngibl","year":"2022","unstructured":"Zirngibl M, Assinck P, Sizov A, Caprariello AV, Plemel JR (2022) Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination. Mol Neurodegener 17:34","journal-title":"Mol Neurodegener"}],"container-title":["Experimental Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00221-026-07294-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00221-026-07294-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00221-026-07294-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:04:37Z","timestamp":1780664677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00221-026-07294-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7294"],"URL":"https:\/\/doi.org\/10.1007\/s00221-026-07294-x","relation":{},"ISSN":["0014-4819","1432-1106"],"issn-type":[{"value":"0014-4819","type":"print"},{"value":"1432-1106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have personal or financial connections that could lead to a conflict of interest regarding the work described in the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"118"}}